<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01202084</url>
  </required_header>
  <id_info>
    <org_study_id>EF 065</org_study_id>
    <secondary_id>CAINAS FF</secondary_id>
    <nct_id>NCT01202084</nct_id>
  </id_info>
  <brief_title>A Study Comparative of Formoterol/Fluticasone Foraseq® and Fluticasone in Asthma Patients</brief_title>
  <official_title>A Phase III, Randomized, Open-label, Non-inferiority Study Comparative of Formoterol/Fluticasone Eurofarma 12/250 µg, Foraseq® 12/400 µg and Fluticasone 500 µg in Asthma Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eurofarma Laboratorios S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eurofarma Laboratorios S.A.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective will be to compare the impact of the study formulations on pulmonary
      function in persistent asthma carriers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Actual">November 2012</completion_date>
  <primary_completion_date type="Actual">November 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Forced expiratory volume in 1 second (FEV1) at final visit.</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Peak expiratory flow (PEF)</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">222</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Formoterol/Fluticasone Eurofarma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>formoterol + fluticasone (12/250 mcg) twice a day per 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Foraseq®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>formoterol + budedonide (12/400 mcg) twice a day per 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fluticasone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>fluticasone (500 mcg) twice a day per 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Formoterol/Fluticasone</intervention_name>
    <arm_group_label>Formoterol/Fluticasone Eurofarma</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Foraseq®</intervention_name>
    <arm_group_label>Foraseq®</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluticasone</intervention_name>
    <arm_group_label>Fluticasone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Sign the ICF

          -  Age ≥ 12 years

          -  Persistent asthma diagnosis, as per the GINA classification (www.ginasthma.com),18
             with symptoms for at least 6 months and clinically stable for at least 1 month, with
             the ACQ-745 test (see Appendix C) ≤ 3.0

          -  Current use of inhaled corticosteroid (beclomethasone dipropionate dose of up to 1000
             µg), associated or not with long-term β2-adrenergic agents and breakthrough medication
             (salbutamol or equivalent)

          -  Initial FEV1 of at least 40% of the predicted normal value

          -  Serum cortisol assessment within normal values.

        Exclusion Criteria:

          -  Use of oral or parenteral corticosteroid within the 3 months prior to study beginning

          -  Requirement of admission due to asthma within the 3 months prior to study beginning

          -  Presence of active smoking, defined as the use of cigarette, pipe, cigar or any form
             of smoking at any amount within the last 3 months

          -  Presence of severe co-morbidities, such as cardiovascular, renal, liver, neurological,
             neoplastic, hematological, infectious, dermatological, neurological, psychiatric or
             chronic respiratory disease other than asthma

          -  Recent (&lt; 6 months) or predicted participation during this study in other clinical
             studies involving drugs of any nature or in studies of any form of intervention for
             treating asthma

          -  Intolerance or allergy to any of the components of the drugs assessed in the study

          -  Pregnancy or lactation

          -  Chronic use of β-blocker medications, per routine oral or intravenous route, or also
             as ophthalmic solutions
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>IMA Brasil - Instituto de Pesquisa Clínica e Medicina Avançada</name>
      <address>
        <city>São Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>May 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 14, 2010</study_first_submitted>
  <study_first_submitted_qc>September 14, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 15, 2010</study_first_posted>
  <last_update_submitted>June 17, 2015</last_update_submitted>
  <last_update_submitted_qc>June 17, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 18, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluticasone</mesh_term>
    <mesh_term>Formoterol Fumarate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

